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Abstract
Background: The delivery of therapeutic genes to the central nervous system (CNS) using viral vectors
represents an appealing strategy for the treatment of nerve injury and disorders of the CNS. Important
factors determining CNS targeting include tropism of the viral vectors and retrograde transport of the
vector particles. Retrograde transport of equine anemia virus (EIAV)-based lentiviral vectors pseudotyped
with the glycoprotein derived from the Rabies virus RabERA strain from peripheral muscle to spinal motor
neurons (MNs) was previously reported. Despite therapeutic effects achieved in mouse models of
amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), the efficiency of this approach
needs to be improved for clinical translation. To date there has not been a quantitative assessment of
pseudotyped HIV-1-based lentiviral vectors to transduce MNs. Here, we describe quantitative tests to
analyze the retrograde transport capacity of HIV-1 vectors pseudotyped with the G glycoprotein derived
from Rabies and Rabies-related viruses (Lyssaviruses).
Methods: With a view toward optimizing the retrograde transport properties of HIV-1-based lentiviral
vectors, we compared the glycoproteins from different enveloped viruses belonging to the Rhabdoviridae
family, genus Lyssavirus, and evaluated their ability to transduce specific cell populations and promote
retrograde axonal transport. We first tested the transduction performance of these pseudotypes in vitro
in SH-SY5Y neuroblastoma cells, NSC-34 neuroblastoma-spinal cord hybrid cells, and primary mixed
spinal cord and pure astrocyte cultures. We then analyzed the uptake and retrograde transport of these
pseudotyped vectors in vitro, using Campenot chambers. Finally, intraneural injections were performed to
evaluate the in vivo retrograde axonal transport of these pseudotypes.
Results: Both the in vitro and in vivo studies demonstrated that lentiviral vectors pseudotyped with the
glycoprotein derived from the Rabies virus PV strain possessed the best performance and neuronal
tropism among the vectors tested.
Conclusion: Our results indicate that HIV-1-based lentiviral vectors pseudotyped with the Rabies PV
glycoprotein might provide important vehicles for CNS targeting by peripheral injection in the treatment
of motor neuron diseases (MND), pain, and neuropathy.
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Background
Lentiviral and adeno-associated viral (AAV) vectors are the
most promising vectors in the field of gene transfer for
neurodegenerative diseases [1-3]. The larger cloning
capacity of lentiviral vectors, however, makes them more
suitable for therapeutic purposes. A variety of primate len-
tiviral vectors including vectors based on HIV-1 [4,5] and
simian immunodeficiency virus (SIV) [6], or on non-pri-
mate lentiviral vectors such as EIAV [7,8] and feline
immunodeficiency virus (FIV) [9] have been shown to
mediate significant transgene delivery in the mammalian
nervous system. Finally, lentiviral-based gene transfer
strategies have been widely tested for the treatment of
neurological disorders, such as Parkinson's disease (PD),
Alzheimer's disease (AD), Huntington's disease (HD),
spinal cord injury, metabolic disorders, and MND [2,10-
12]. We have recently reviewed the existing gene therapy
strategies for MND [13]. Although direct vector injection
has been reported [8,14], gene delivery to spinal cord
MNs by retrograde axonal transport following muscle
injection is the main strategy being currently explored
[8,15-17].
It has been well documented that the tropism of lentiviral
vectors can be altered using pseudotyping strategies,
which consist in the replacement of the vector envelope
glycoprotein for alternative glycoproteins derived from
other enveloped viruses. A wide range of viral envelope
glycoproteins, including those from Rabies and Mokola
viruses have been used for pseudotyping [18]. However,
considerable differences in the brain transduction pat-
terns were demonstrated even between related Lyssavirus-
derived glycoproteins. For example, transduction of the
mouse striatum by HIV-1 vectors pseudotyped with the
glycoprotein derived from a Zimbabwean Mokola virus
was inefficient [19,20], while HIV-1 vectors bearing an
Ethiopian Mokola virus glycoprotein revealed robust
transduction [21,22].
To date there has not been a quantitative assessment of
pseudotyped HIV-1-based lentiviral vectors to transduce
MNs. In the present study, we compared four different
titer-adjusted HIV-1 vector pseudotypes bearing envelope
glycoproteins from Rabies-related viruses, such as the
European Bat Lyssavirus (EBL1), the Lagos Bat Lyssavirus
(LagNGA), the Duvenhage (DuvSAF1) Lyssavirus, and
Rabies PV virus [23] in terms of their transduction effi-
ciencies in vitro and in vivo. We found that lentiviral vec-
tors pseudotyped with the Rabies PV G-glycoprotein had
the best performance in all the assays conducted, being,
therefore, a promising candidate for future gene delivery
strategies involving pseudotyped HIV-1-based lentiviral
vectors.
Methods
Cell culture
Cell lines
293T cells (CRL-11268), human osteosarcoma (HOS)
cells (CRL-1543) and BHK21 cells (CCL-10) were
obtained from the American Type Culture Collection
(ATCC). DMEM/10% FBS (Invitrogen) was used to prop-
agate 293T and HOS cells and Eagle's Minimum Essential
Medium (EMEM)/10% FBS for BHK21 cells. Human neu-
roblastoma SH-SY5Y cells (ATCC CRL-2266) were grown
to 70% confluence and maintained in a growth medium
containing a 1:1 mixture of EMEM and Ham's F12
medium (90%) (Invitrogen), supplemented with 10%
FBS (HyClone). Medium was renewed every 2 days. The
NSC-34 neuroblastoma-spinal cord hybrid cell line [24]
was provided by Dr. Neil Cashman, Toronto. NSC-34 cells
were propagated in DMEM/10% FBS.
Astrocyte cultures
Astrocytes were isolated from embryonic day 15 mouse
cerebral cortices and kept in 75-cm2 flasks coated with
poly-D-lysine containing a 1:1 mixture of DMEM and
Ham's F12 medium supplemented with 5% FBS, 5%
horse serum, 2 mM GlutaMAX, 100 U/ml penicillin and
100 mg/ml streptomycin. For transduction, cells were har-
vested and plated into 8-well chamber slides (Nalge
Nunc) coated with poly-D-lysine.
Mixed spinal cord cultures
Spinal cords were obtained under sterile conditions from
15-day Sprague Dawley rat embryos. Dorsal root ganglia
(DRGs) and perineural membranes were removed and
cords cut into approximately 2-mm sections, which were
then triturated and dissociated in a 0.05% trypsin/0.53
mM EDTA solution. Cells were collected, centrifuged for 5
min at 1800 rpm, and resuspended in complete growth
medium made in supplemented Neurobasal Medium
(Invitrogen-GIBCO). Cells were plated on glass coverslips
in multi-well cell culture plates pre-coated with poly-L-
lysine (24 h, 0.005% in H2O).
Compartmentalized chambers
DRGs were carefully removed from 15-day-old Sprague-
Dawley rat embryo cords and cultured following an estab-
lished protocol [25]. Briefly, DRG explants were plated
into the inner compartments of Campenot compartmen-
talized chambers [26] in a small volume of medium and
allowed to adhere for two hours. The chambers were pre-
pared as follows: 35-mm cell culture dishes were pre-
coated with a diluted collagen solution (three parts of ster-
ile distilled H2O to one part of rat tail collagen type I – 2
mg/ml – Roche Diagnostics Corp.). Scratches were then
made in the collagen substratum using a pin rake, to guideGenetic Vaccines and Therapy 2009, 7:1 http://www.gvt-journal.com/content/7/1/1
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axon growth. A drop of medium was placed onto the plate
before setting the divider onto the culture dish, in order to
facilitate axon growth underneath the silicon grease barri-
ers. Teflon chamber dividers (Tyler Research) were then
carefully attached to the collagen-coated dishes using sili-
cone vacuum grease (Dow Corning). After 1 h in the incu-
bator, the inner compartments of the chambers were filled
with culture medium to check for leakage. Chambers that
showed any leakage were discarded and those that
appeared well-sealed were filled with culture medium.
Fluorescence was also used to demonstrate the absence of
leakage between chambers, by adding a fluorescent tracer
(DiI – Molecular Probes, Invitrogen Corporation) in the
inner compartment. The compartments were then filled
with growth medium, consisting of Neurobasal medium
supplemented with B-27 additive (Invitrogen), 50 ng/ml
of Nerve Growth Factor 2.5S (NGF) (Invitrogen), and 40
μM of 5'-Fluoro-2'-deoxyuridine – FUDR (Sigma-
Aldrich). The outer compartments were filled with growth
medium supplemented with 100–200 ng/ml of NGF to
coax neurite growth into these compartments. Cells were
re-fed every other day. The outer compartments were also
re-filled every other day with growth medium supple-
mented with NGF.
β-Gal staining and immunocytochemistry (ICC)
SH-SY5Y cells and mixed spinal cord cell cultures were
processed for β-Gal staining 3 days after transduction
using an X-Gal staining kit (Invitrogen). In order to iden-
tify neurons and glia in the cultures transduced with the
EGFP-encoding vectors, ICC was performed with anti-
body directed against microtubule associated protein 2
(Map-2) and glial fibrillary acidic protein (GFAP). The
Map-2 antibody (Covance Research Products) was used at
a concentration of 1:10,000 and anti-GFAP antibody
(Promega) at a concentration of 1:1000. Fluorescent cells
were visualized using a Nikon E400 upright microscope.
Lentiviral vectors
Plasmid constructs
The pNL-EGFP/CMV/WPREΔ U3 lentivirus vector plas-
mid was described before [27]. In the pNL-EGFP/lacZco/
WPREΔ U3 lentiviral vector plasmid [28], a codon-opti-
mized lacZ gene sequence encoding β-galactosidase (β-
Gal) [29] was used to replace the EGFP transgene
sequence. The VSV-G-encoding pLTR-G plasmid was
described before [30]. Plasmids encoding glycoproteins of
the Rabies virus PV strain (GenBank Accession number:
A14671), Duvenhage virus (DuvSAF2 strain) (GenBank
Accession number: AF298147), European bat Lyssavirus
(EBL1FRA strain) (GenBank Accession number:
AF298143) and Lagos bat Lyssavirus (LagNGA strain)
(GenBank Accession number: AF298148) [23] were con-
structed as follows: Total RNA was extracted from BHK-21
cells infected with the various Lyssavirus isolates and
reverse-transcribed using an ImProm-II Reverse Transcrip-
tion System (Promega) and primers corresponding to the
3'-untranslated regions of the various viral RNAs. The
primers used for reverse transcription were: Rabies PV: 5'
CGG GAT CCG GCC AGC TCT CAC AGT CCG GT;
DuvSAF: 5' CGG GAT CCC TCT CAC TCC CTT GTT GAT
GG; EBL1: 5' CGG GAT CCT GCT TAT GAC TCA CAA GTA
GT; LagNGA: 5' GGA ATT CTT GTT ACC ATG AGT CAA
CTA AAA. The glycoprotein coding regions were subse-
quently PCR amplified using AccuPrime™ Pfx DNA
Polymerase (Invitrogen) and subcloned into pLTR [30] to
yield pLTR-PV, pLTR-DuvSAF, pLTR-EBL1 and pLTR-
LagNGA, respectively. The primers used for PCR were as
follows: Rabies PV: 5' GGA ATT CCA AGG AAA GAT GGT
TCC TCA G (sense), 5' CGG GAT CCG GCC AGC TCT
CAC AGT CCG GT (antisense); DuvSAF: 5' GGA ATT CAC
CAT GCC ACT CAA TGC AGT CA (sense), 5' CGG GAT
CCC TCT CAC TCC CTT GTT GAT GG (antisense); EBL1:
5' GGA ATT CAC CAT GTT ACT CTC TAC CGC CA
(sense), 5' CGG GAT CCT GCT TAT GAC TCA CAA GTA
GT (antisense); LagNGA: 5' CCC CCG GGA TCA GAC ATT
AGA GCT ACC CT (sense), 5' GGA ATT CTT GTT ACC
ATG AGT CAA CTA AAA (antisense). All glycoprotein-
encoding sequences were analyzed by DNA sequencing.
Sciatic nerve injections
All animal procedures were approved by the Animal Care
and Use Committee and strictly adhered to the require-
ment set forth by the Guide for the Care and Use of Labo-
ratory Animals. Sciatic nerve injections were performed as
previously described [37]. Briefly, adult male Sprague
Dawley rats (Harlan), weighing 275–300 g, were anesthe-
tized with nose-cone isoflurane (2% in O2). The lateral
surface of the right thigh was shaved, sterilized, and a skin
incision was made parallel to the femur. Using a dissect-
ing microscope (StereoZoom 6; Leica), the sciatic nerve
was exposed and a 5-0 silk suture was tied to provide gen-
tle counter traction during the nerve injection. To crush
the nerve, a clamp was placed around the nerve immedi-
ately before the tie, closed to the first lock and then
released. Using an automatic microinjector (Nanoject II;
Drummond), nerves were injected with 2 μl of the differ-
ent β-Gal-encoding pseudotypes (n = 5/group), adjusted
at 1.25 × 104 TU per μl. After injection, the femoral mus-
culature was reapproximated and the skin stapled. Ani-
mals were monitored for limb weakness, paralysis, and
infection, as well as for symptoms of neurogenic pain
including limb mutilation. Animals were euthanized 4
weeks after injections.
β-Gal staining and histology
For histological analyses, rats were deeply anesthetized
with sodium pentobarbital (100 mg/kg, I.P.) and transcar-
dially perfused with a 0.9% saline solution, followed by
4% paraformaldehyde (Sigma-Aldrich) in phosphateGenetic Vaccines and Therapy 2009, 7:1 http://www.gvt-journal.com/content/7/1/1
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buffer saline (PBS), pH 7.4. Sciatic nerves, DRGs, and spi-
nal cords were dissected, post-fixed for 24 h, and trans-
ferred to a 30% solution of sucrose. Tissues were first
processed for β-Gal staining and then frozen in optimal
cutting temperature gel (OCT; Sakura Finetek USA) and
stored until histological processing. Nerves, DRGs, and
spinal cords were cut at 25 μm in transverse sections on a
cryostat (Leica Microsystems) and mounted onto slides.
Counter-staining was performed on transverse sections
using Eosin. Finally, the slides were mounted with cover-
slips using Permount mounting medium (Fisher Scien-
tific).
Quantitative analysis
All the experiments were performed at least in triplicate.
In order to derive the percentage of transduced cells,
images were acquired by a Nikon E400 microscope using
a DS-Qi1 High-sensitivity Cooled CCD camera and ana-
lyzed using the NIS-Elements imaging software (Nikon
Instruments, Inc). Cells were counted in 10 randomly
fields per slide and the mean percentages of positive cells
were calculated. For quantification of transduction in the
chambers, the fluorescence pixel intensity within the DRG
cell bodies was quantified. Data is expressed as mean ±
standard deviation (SD).
Statistical Analysis
Individual conditions (such as the effect of different vec-
tor treatments) were compared and statistically analyzed
for significance with one-way analysis of variance
(ANOVA) and post hoc Tukey tests using the Jandel Sigm-
aStat software. Combined effects of vector treatment/MOI
or vector treatment/astrocyte culture (mixed or pure) were
compared with a two-way ANOVA test.
Results
Titration of lentiviral vectors bearing lyssavirus 
glycoproteins
To compare the performance of the various pseudotypes it
was important to accurately adjust the vector's multiplici-
ties of infection (MOI) prior to transduction. This brought
up the issue as to what technique would be most suitable
to determine the titers. Currently, there are different meas-
ures available to determine lentiviral vector titers [18].
Some of them rely on the number of vector particles
present in a vector stock based on strong-stop cDNA or on
viral RNA present in virions [38,39]. Others are based on
the amount of virus proteins present in vector cores such
as p24 Gag [40]. Functional titration assays are based on
vector-encoded reporter gene expression. For example,
vectors encoding β-Gal have been titrated using X-Gal
staining [28]. Also significant for titration is the cell line
used as receptors for a given pseudotype may vary from
cell line to cell line, possibly producing a falsely depressed
titer.
To accurately compare the performance of the various
pseudotypes, we tested two different titration protocols to
adjust vector MOIs including protocols based on func-
tional titers and protocols based on particle titers.
Transduction efficiencies of titer-adjusted lentiviral vector 
pseudotypes using functional titers
To first determine the efficiency with which these vectors
could transduce neuronal cells, we used SH-SY5Y cells. In
this experiment, vector MOIs were adjusted based on
functional titers (TU). Overall, Rabies PV-pseudotyped
vectors performed better than the other pseudotypes in
this assay, transducing 20.76 (± 1.1) and 36.78 (± 1.05) %
of the cells at MOIs 0.1 and 1, respectively (Figure 1).
Moreover, it was interesting to note that only the trans-
duction efficiency of Rabies PV-treated cells significantly
Transduction of SH-SY5Y cells using lentiviral vectors pseu- dotyped with different lyssavirus glycoproteins Figure 1
Transduction of SH-SY5Y cells using lentiviral vec-
tors pseudotyped with different lyssavirus glycopro-
teins. SH-SY5Y neuroblastoma cells were transduced using 
β-Gal-encoding lentiviral vectors pseudotyped with Rabies-
PV, DuvSAF, LagNGA, and EBL1 glycoproteins. MOIs were 
adjusted based on functional titers (TU) determined on 
BHK-21 cells. Cells were processed for X-gal staining 3 days 
after treatment. At an MOI of 0.1 (white bars), 20.76 ± 1.1% 
of the cells were positive following transduction with the 
Rabies PV-pseudotyped vector, while only 11.56 ± 0.78% of 
the cells treated with the DuvSAF vector were positive. The 
LagNGA and the EBL1-pseudotyped vectors transduced 1.32 
± 0.20% and 1.25 ± 0.18% of cells, respectively. At an MOI of 
1 (black bars), a similar pattern of transduction was 
observed. The Rabies PV and the DuvSAF vectors trans-
duced 36.78 ± 1.05% and 13.13 ± 1.14% of the cells. The 
EBL1 pseudotype and the LagNGA vectors transduced 3.17 
± 0.35% and 2.79 ± 0.09% of the cells, repsectively. The 
transduction efficiency of Rabies PV-treated cells was the 
only one that increased as a result of a higher MOI (* p < 
0.05).Genetic Vaccines and Therapy 2009, 7:1 http://www.gvt-journal.com/content/7/1/1
Page 5 of 9
(page number not for citation purposes)
increased as a result of a higher MOI (two-way ANOVA, p
< 0.05).
Transduction efficiencies of titer-adjusted lentiviral vector 
pseudotypes using particle titers
In this set of experiments, MOIs were adjusted based on
particle titers determined by quantitative RT-PCR of vir-
ion-derived RNA to rule out effects caused by differences
in receptor levels in target cells. Particle titer-adjusted
pseudotypes were tested in the NSC-34 neuroblastoma-
spinal cord hybrid cell line [24]. Vectors encoding EGFP
were used to facilitate the analysis of transduced cells by
flow cytometry (FACS). HOS cells that are easily trans-
duced by lentiviral vectors [30,36] were tested in parallel
to compare the performance of the various pseudotypes
(data not shown). Cells were processed for FACS 3 days
after treatment as described [33]. The results presented in
Figure 2 indicate that at an MOI of 5 × 103 vector particles
per cell, Rabies PV pseudotypes transduced 49.9% of
NSC-34 cells, while the performance of all other pseudo-
types was considerably lower, including a VSV-G pseudo-
type that was used for comparison.
Relative transduction efficiencies of lyssavirus-pseudotyped lentiviral 
vectors in E15 rat mixed spinal cord cultures
The vectors were then tested in mixed spinal cord cultures
to assess their potential specificity for neurons as opposed
to glial cells. Cultures from 15 day-old rat embryos were
transduced and processed 3 days later for cell identifica-
tion. Two different kinds of vectors were used: vectors
encoding β-Gal (103 vector particles per cell) and vectors
encoding EGFP (104 vector particles per cell). Overall, the
transduction efficiencies in mixed spinal cord cultures
were similar to those observed in SH-SY5Y and NSC-34
cells, i.e. vectors pseudotyped with the Rabies PV glyco-
protein revealed the highest transduction efficiency to
neurons (70.35 ± 9.66% of transduced cells) (Figures 3A
and 3B) followed by the others. The difference between
vectors reached significance in all groups (p < 0.05).
Because all the vectors were able to transduce glial cells at
some level in mixed cultures (Figure 3C – dark gray bars),
we decided to investigate this effect in more detail using
primary pure astrocytes. Indeed the results presented in
Figure 3C show that all pseudotypes have the ability to
transduce astrocytes in either mixed or pure astrocyte pop-
ulations. Interestingly, the effect of the culture type
(mixed or pure) did not affect the pattern of transduction
in the Rabies PV, LAgNGA, and EBL1 conditions. The per-
centage of transduced astrocytes by VSV-G and DuvSAF
pseudotyped vectors, however, significantly decreased in
pure astrocytes compared to mixed cultures (Figure 3C). A
two-way ANOVA analyzing vector and culture type
revealed a significant effect in these particular groups (*,
** p < 0.05).
Retrograde transport of vector particles
Uptake and retrograde transport in vitro using Campenot chambers
Aiming at using these pseudotypes as vehicles for CNS tar-
geting by peripheral injection, we then evaluated their
uptake when peripherally applied to axons terminals. For
this purpose, DRG explants grown in compartmented
chambers were used. The MOIs of vectors were normal-
ized based on particle titers and 10 μl (2 × 108 vector par-
ticles total) of each pseudotyped vector were added to the
chambers. Only one outer compartment of the chambers
containing axon terminals was treated and, 3 days later,
fluorescence was assessed in the central compartment
Transduction of NSC-34 cells using lentiviral vectors pseudotyped with different lyssavirus glycoproteins Figure 2
Transduction of NSC-34 cells using lentiviral vectors pseudotyped with different lyssavirus glycoproteins. NSC-
34 neuroblastoma-spinal cord hybrid cells (2 × 105 cells) were transduced using EGFP-encoding lentiviral vectors pseudotyped 
with Rabies-PV, DuvSAF, LagNGA or EBL1 glycoproteins. A VSV-G vector was also used for comparison this time. MOIs were 
adjusted based on particle titers determined using virion RNA and 5 × 103 vector particles per cell were used. Cells were proc-
essed for FACS 3 days later. The Rabies PV pseudotypes transduced 49.9% of NSC-34 cells, while the performance of all other 
pseudotypes was considerably lower. The VSV-G vector transduced 7.9% of the cells, followed by the EBL1 (5.00%), LagNGA 
(1.9%) and DuvSAF (1.0%).Genetic Vaccines and Therapy 2009, 7:1 http://www.gvt-journal.com/content/7/1/1
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containing the cell bodies. When vectors were directly
added to the inner compartment containing the DRG cell
bodies, fluorescence could be detected with all the pseu-
dotypes (data not shown). On the other hand, when vec-
tors were added to the compartments containing the axon
terminals, fluorescence could only be detected in DRG
explants of chambers treated with the Rabies PV and the
DuvSAF vectors (Figure 4), indicating their ability to be
taken up and be retrogradely transported to the cell bodies
of the DRG explants.
Uptake and retrograde transport in vivo
In order to assess the uptake and retrograde axonal trans-
port of our pseudotyped lentiviral vectors in vivo, we next
In vitro transduction of neurons and glia by lentiviral vectors pseudotyped with different lyssavirus glycoproteins Figure 3
In vitro transduction of neurons and glia by lentiviral vectors pseudotyped with different lyssavirus glycopro-
teins. Primary cell cultures were transduced using pseudotyped vectors encoding β-Gal (103 vector particles per cell) or EGFP 
(104 vector particles per cell) and processed 3 days later for cell identification. A) Quantification of the percentage of trans-
duced neurons in primary embryonic mixed spinal cord cultures demonstrated that the Rabies PV pseudotype transduced 
70.35 ± 9.66% of the neurons. The VSV-G vector transduced 13.98 ± 1.39% of the neurons and the DuvSAF-pseudotyped vec-
tor transduced 4.68 ± 3.58% of the cells. No transduced neurons could be detected in the LagNGA and EBL1 conditions. The 
difference between vectors reached significance in all groups (#, ##, ### p < 0.05). B) Immunocytochemistry data revealing 
the neuronal pattern of transduction observed after treatment with the Rabies PV pseudotype in primary mixed spinal cord 
cultures. Cells were stained for Map-2 (red) for identification of EGFP-positive neurons. Arrowheads indicate transduced 
astrocytes (GFP-positive/Map-2 negative cells). Scale bar = 50 μm. C) Quantification of the percentage of transduced astro-
cytes in mixed spinal cord (dark gray bars) vs. pure astrocyte cultures (light gray bars) demonstrated that all pseudotypes have 
the ability to transduce astrocytes with no effect of the culture type (mixed or pure) in the Rabies PV, LAgNGA, and EBL1 con-
ditions, but a statistically significant decrease effect in the VSV-G and DuvSAF groups (*, ** p < 0.05).Genetic Vaccines and Therapy 2009, 7:1 http://www.gvt-journal.com/content/7/1/1
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used the remote viral gene delivery model [37,41]. 2.5 ×
104 TU of the different pseudotypes in a volume of 2 μl
were injected into the crushed sciatic nerve of rats. To
allow optimal transgene expression, animals were eutha-
nized after 4 weeks and sciatic nerves, ipsilateral lumbar
DRGs, and lumbar spinal cords were removed for analy-
sis. Sections were stained using X-Gal to visualize β-Gal
expressing cells. While all the vectors mediated some kind
of retrograde transport to DRGs in vivo, β-Gal transgene
expression was only observed in ventral horn motor neu-
rons of the spinal cords injected with the Rabies PV-pseu-
dotyped vector (Figure 5).
Discussion
We have shown that HIV-1-based lentiviral vector parti-
cles can be pseudotyped with glycoproteins from different
members of the Lyssavirus genus/Rhabdoviridae family. By
analyzing the performance of these pseudotyped vectors
using particle titer-adjusted vector stocks, we have demon-
strated their distinct patterns of transduction in vitro.
Finally, uptake and retrograde axonal transport have been
evaluated both in vitro using compartmentalized cham-
bers and in vivo using sciatic nerve injections. We were
able to consistently reproduce our initial observations
throughout the assays and, among all the pseudotypes
tested, the Rabies PV virus-derived G glycoprotein [23]
possessed the best performance and neuronal tropism.
We believe that the assays described herein will be gener-
ally useful to characterize the retrograde transport charac-
teristics of other pseudotypes in the future.
Retrograde transport of gene therapy vectors offers a
potentially powerful strategy for targeting specific neuro-
nal populations in vivo. A variety of pseudotyped lentiviral
vectors have been demonstrated to transduce neuronal
cells and to undergo retrograde transport [18,42]. In
rodents, through direct or peripheral delivery, these stud-
ies have compared the CNS transduction patterns of dif-
ferent EIAV- and HIV-1-based vector pseudotypes.
In vitro uptake and retrograde transport of pseudotyped lenti- viral vectors Figure 4
In vitro uptake and retrograde transport of pseudo-
typed lentiviral vectors. DRG explants were plated in the 
central compartment of compartmentalized chambers. Left 
and right side compartments were filled with growth media 
supplemented with NGF to coax neurite growth into these 
compartments. The right compartments containing axon ter-
minals were treated with equivalent concentrations of Rabies 
PV, DuvSAF, LagNGA, or EBL1-pseudotyped vectors (2 × 
108 vector particles total) and fluorescence was analyzed 4 
days later. A VSV-G pseudotyped vector was used as a nega-
tive control. For quantification of transduction, the fluores-
cence pixel intensity within the DRG cell bodies was 
quantified. Fluorescence could only be detected in DRG 
explants of chambers treated with the Rabies PV (57.12 ± 
1.70%) and the DuvSAF (20.6 ± 5.27%) vectors, indicating 
their exclusive ability to be taken up and be retrogradely 
transported to the cell bodies of the DRG explants as 
opposed to the other pseudotypes. Differences between 
vectors were statistically significant in all groups (#, ## p < 
0.05). Scale bar = 20 μm. In vivo uptake and retrograde transport of the Rabies PV- pseudotyped lentiviral vector Figure 5
In vivo uptake and retrograde transport of the Rabies 
PV-pseudotyped lentiviral vector. A total of 2.5 × 104 
TU in a volume of 2 μl were injected into the crushed sciatic 
nerve of rats. Animals were euthanized after 4 weeks. An X-
gal staining kit was used to detect cells expressing the trans-
gene. Eosin was used for counter-staining. While all the vec-
tors mediated some kind of retrograde transport to DRGs, 
β-Gal transgene expression could only be detected in motor 
neurons of the spinal cord (arrows) of animals injected with 
the Rabies PV-pseudotyped vector. Scale bars = 50 μm (A), 1 
mm (A').Genetic Vaccines and Therapy 2009, 7:1 http://www.gvt-journal.com/content/7/1/1
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Overall, vectors pseudotyped with VSV-G or Rabies virus
G-glycoproteins including those from the Evelyn-Rokit-
nicki-Abelseth (ERA) strain [8,15] or the challenge virus
standard strains CVS, CVS-B2c and CVS-N2c [8,17,43]
were shown to preferentially transduce neurons. How-
ever, transduction of astrocytes with ERA-pseudotyped
EIAV vectors was also apparent [8,15]. The main differ-
ence reported was the ability of Rabies-G but not VSV-G
pseudotyped vectors to undergo retrograde transport to
appropriate distal neurons of the lumbar spinal cord after
peripheral delivery [8,15,17]. In summary, these results
demonstrated that targeted transduction in the CNS can
be achieved using specific glycoproteins to pseudotype
lentiviral vectors. Moreover, EAIV vectors pseudotyped
with the ERA and CVS glycoproteins [8,15] and HIV-1 vec-
tors pseudotyped with the CVS-B2c glycoprotein [17]
have been proven to be attractive candidates when MNs
are the main target. One problem with the above studies
is that different assays were used to determine vector titers,
making a direct comparison of the results difficult. Some
of the assays used involved functional (biological) titers
determined on a variety of different cell lines including
canine osteosarcoma (D17) cells [8] and human 293T
cells [43]. Other assays involved p24 antigen levels deter-
mined by ELISA [17,20]. While functional titers deter-
mined on heterologous cell lines may underestimate
vector titers, particle assays based on p24 can be mislead-
ing because they do not necessarily reflect intact vector
particles only [27].
Based on the transduction experiments conducted with
SH-SY5Y, NSC-34 and mixed spinal cord and astrocyte
cultures, there appear to be differences among the various
pseudotypes tested in terms of cellular tropism, possibly
due to differences in the receptors used by the various
pseudotypes. A variety of putative cellular receptors have
been described for Rabies virus including the acetylcho-
line receptor and the low-affinity nerve-growth factor
receptor (P75NTR) [44]. However, there appear be addi-
tional receptors as lentivector pseudotypes bearing Lyssa-
virus glycoproteins have been shown to be capable of
transducing a variety of cell lines and primary cells sup-
posedly lacking the above receptors [8,17,36]. The use of
cell specific-promoters can restrict distribution and spe-
cific gene expression to the desired populations.
EIAV-based lentiviral vectors have been recently used to
peripherally deliver therapeutic proteins on mouse mod-
els of familial ALS and SMA [45,46]. Although successful
in young mice, the efficiency of these approaches remains
to be determined in larger species. It is currently unknown
whether in the context of gene therapy trials in humans
these vectors will ultimately be able to transduce a suffi-
cient number of MNs to make a therapeutic impact. Thus,
further attempts aimed at improving the retrograde trans-
port of these vectors will be necessary.
Lentiviral vectors have reached the clinical trial stage [47]
and clinical translation of such vectors aimed at treating
MN disorders may ultimately be feasible. Lentiviral vec-
tors combine the advantages of long-term transgene
expression, minimal immunogenicity, ability to accom-
modate larger transgenes, and the capacity to form pseu-
dotypes with a wide variety of different glycoproteins.
Thus, this novel Rabies PV G-pseudotyped HIV-1-based
vector might be an important vehicle for remote gene
delivery in the treatment of MN diseases, pain, and neu-
ropathy.
Conclusion
Our results indicate that HIV-1-based lentiviral vectors
pseudotyped with the Rabies PV glycoprotein might pro-
vide important vehicles for CNS targeting by peripheral
injection in the treatment of motor neuron diseases, pain,
and neuropathy.
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